Skip to main content
Signal8

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc.

OTC:RVPHOTC (suspended from Nasdaq on May 14, 2026)Healthcare
+1.30%$0.3550
CLOSED
Mkt Cap$4.65M
EV-
Float12.86M
O/S13.11M
VOL7K sh
$ Vol$3K
RVOL0.22×
Inst Own0.1%
SI3.1%
Net Cash/Sh-
Dilution
Reviva Pharmaceuticals Holdings, Inc. logoOTC:RVPHClosed$0.3550+1.30%
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›